Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer

Immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy (CT) are the current standard of therapy in several cancer types. Patients (pts) with lung cancer display higher response rates to CT when given after ICIs. Although ICIs have failed to demonstrate antitumour activity in microsatellite stable (MSS) metastatic colorectal cancer (mCRC), little is known about CT effect after ICIs. We aimed to assess whether sequential ICIs followed by CT may be an alternative therapeutic approach in a population of pts with mCRC.

Source: European Journal of Cancer - August 1, 2020 Category: Cancer & Oncology Authors: Patricia Martin-Romano, Samy Ammari, Yolla El-Dakdoukti, Capucine Baldini, Andreea Varga, Perrine Vuagnat, Eric Angevin, Rastislav Bahleda, Anas Gazzah, Stephane Champiat, Jean M. Michot, Sophie Postel-Vinay, Aurelien Marabelle, Jean C. Soria, Valerie Boi Tags: Original Research Source Type: research